Insulet (PODD) to Release Quarterly Earnings on Wednesday

Insulet (NASDAQ:PODD) will likely be posting its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Insulet to post earnings of $1.19 per share and revenue of $729.8870 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.15 earnings per share. On average, analysts expect Insulet to post $6 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Insulet Stock Performance

Insulet stock opened at $171.39 on Tuesday. Insulet has a twelve month low of $158.35 and a twelve month high of $354.88. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $11.87 billion, a P/E ratio of 48.97, a PEG ratio of 1.03 and a beta of 1.20. The stock’s 50 day moving average is $216.37 and its 200 day moving average is $267.14.

Analysts Set New Price Targets

Several research firms have recently issued reports on PODD. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $325.00 price target on shares of Insulet in a research report on Tuesday, April 14th. Citigroup lowered shares of Insulet from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $338.00 to $230.00 in a research note on Tuesday, April 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Weiss Ratings upgraded shares of Insulet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday. Finally, Barclays reiterated an “underweight” rating and set a $286.00 price target on shares of Insulet in a report on Thursday, February 19th. Eighteen analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $327.24.

Insiders Place Their Bets

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet in the fourth quarter worth approximately $26,000. DV Equities LLC purchased a new stake in Insulet during the 4th quarter valued at $28,000. Mcguire Capital Advisors Inc. bought a new position in shares of Insulet during the 4th quarter valued at $29,000. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its holdings in shares of Insulet by 68.8% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 55 shares during the period. Finally, Measured Wealth Private Client Group LLC purchased a new position in shares of Insulet in the 3rd quarter worth $49,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.